Assessing the Impact of the Potential U.S.-Mexico Border Closing on Private Equity Backed Companies

Many of our private equity clients with portfolio companies, factories or suppliers in Mexico have asked for our point of view on the potential U.S.-Mexico border closing. Based on TriVista’s experience, and recent discussions with several Maquiladoras (U.S. companies based in Mexico), we have outlined our perspective on several scenarios and outcomes. Background: The current… Read More

The Case for Sell Side Operational Due Diligence

While most private equity firms perform buy side operational due diligence, there is a strong case that many mid-market investors can increase enterprise value by conducting sell side operational due diligence. Sell side operational due diligence is catching on, and for good reason. The process can: Identify key risks that may come to light in the buy side due… Read More

Key Points To Consider For Your Next Bolt-On

As Private Equity (PE) firms continue to evaluate add-on acquisitions, executing a strong roadmap and avoiding any pitfalls should be top of mind. In this article, we provide some guidelines on achieving successful outcomes with your next bolt-on. Continued market competitiveness for good deals has propelled PE firms to use several levers to drive increased… Read More

What Private Equity Investors Need to Know About Pet Food Safety

TriVista’s Food & Beverage expert, Jennifer Frankenberg discusses the opportunities and risks associated with the spike in M&A activity in the pet food and treat industry in Middle Market Growth Magazine. “Over the last 10 years, we have seen Private Equity investment activity in the Pet Food and Treats sector increase substantially, particularly in the middle market…. Read More

FSMA Guide for Private Equity Investors

Food safety continues to be top of mind during due diligence for Private Equity investors. Keeping up with changing industry regulations can be difficult. In this material, learn about the Seven FSMA Rules, what you can do to mitigate your risks, and the implications of noncompliance. Learn why Private Equity should pay attention to FDA’s… Read More